Zylem Biosciences is a biotechnology company developing targeted medicines based on its novel platform technology: A structural analog of natural high-density lipoprotein (HDL). Zylem has developed multiple formulations of therapies across multiple routes of administration, targeting diseases where lipid dysfunction plays a critical role. These include oncology and cardiovascular disease. Zylem’s team of innovative scientists, and experienced drug development management team is strategically built for success.
The mission of Zylem Biosciences is to pioneer first-in-class therapies targeting SR-B1, a previously undruggable target.
The core ZYL construct is a structural analog of natural high-density lipoprotein (HDL). The compound is highly targeted, has a potent sustained effect through its long half-life, and no off-target activity. It reduces cellular cholesterol, a pathogenic characteristic in oncology and cardiovascular disease, while simultaneously reducing inflammation and tuning the immune system. .